Canbridge Pharmaceuticals (HKSE:01228) EPS (Basic): HK$0.03 (TTM As of Dec. 2025)


HKSE:01228 Canbridge Pharmaceuticals Inc HKSE:01228
46 GF Score
Price HK$2.00
GF Value HK$0.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals EPS (Basic)?

Canbridge Pharmaceuticals HKSE:01228 +2.56% 46 EPS (Basic) is HK$0.03 as of Dec. 2025. GuruFocus rates HKSE:01228 with a GF Score™ of 46/100 and a GF Value™ of HK$0.38 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Canbridge Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.12. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.03.

Canbridge Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.03.

Canbridge Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.12. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.23.

During the past 3 years, the average EPS without NRI Growth Rate was 45.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 44.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Canbridge Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 60.60% per year. The lowest was -30.70% per year. And the median was 35.00% per year.

Canbridge Pharmaceuticals  (HKSE:01228) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Canbridge Pharmaceuticals EPS (Basic) Related Terms

Canbridge Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Canbridge Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canbridge Pharmaceuticals EPS (Basic) Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -14.00 -1.27 -0.97 -1.11 0.03

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.62 -0.49 0.15 -0.12
HKSE:01228
46GF Score
Canbridge Pharmaceuticals Inc HKSE:01228
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canbridge Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Canbridge Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(16.37-0)/453.572
=0.04

Canbridge Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-49.072-0)/482.306
=-0.10

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$0.03 mean?
Canbridge Pharmaceuticals (HKSE:01228) has a EPS (Basic) of HK$0.03 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Canbridge Pharmaceuticals and its competitors.
Is Canbridge Pharmaceuticals' EPS (Basic) too high?
Canbridge Pharmaceuticals' current EPS (Basic) is HK$0.03. Overall, Canbridge Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?
Canbridge Pharmaceuticals' EPS (Basic) of HK$0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Canbridge Pharmaceuticals and its competitors. Canbridge Pharmaceuticals's current EPS (Basic) is HK$0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.38, compared to a current price of HK$2.00 — trading 426.3% above its estimated fair value. The current EPS (Basic) is HK$0.03. Canbridge Pharmaceuticals' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current EPS (Basic) is HK$0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of HK$2.00 is trading 426.3% above its estimated GF Value™ of HK$0.38. GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HKSE:01228:

  • EPS (Basic): HK$0.03
  • GF Value™: HK$0.38 vs. price of HK$2.00 (426.3% above fair value)
  • GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canbridge Pharmaceuticals Business Description

Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
46GF Score

Get the complete analysis for HKSE:01228

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.00
Price
HK$0.38
GF Value